Latest ION Beam Application (IOBCF) Headlines
Post# of 4
Posted On: 03/10/2014 6:46:10 AM
Latest ION Beam Application (IOBCF) Headlines
Zevacor Molecular Awards IBA Contract to Build Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
PR Newswire - Mon Nov 04, 4:09PM CST
Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A., (IBA).
IBA to Install the First Commercial 70 MeV Cyclotron Dedicated to the Production of Radiopharmaceuticals in the United States
GlobeNewswire - Mon Nov 04, 12:46AM CST
IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy and radiopharmacy solutions, today announces it has signed a formal contract with Zevacor Molecular for the installation of its Cyclone 70 in the United States. This will be the first commercial 70 MeV Cyclotron dedicated to radiopharmaceuticals production in the country. The installation of the system is worth between $16 and 20 million to IBA. The project financing is fully secured. The Cyclone 70 Cyclotron is expected to be operational in the second half of 2016.
IBA Successfully Concludes Litigation Over Competing Fiducial Marker
Marketwire - Tue Aug 06, 5:08AM CDT
IBA (Ion Beam Applications S.A.) (EURONEXT BRUSSELS: IBAB), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the execution of a Letter of Intent to resolve litigation and claims of IBA subsidiary RadioMed Corp. against ONC Solutions, Inc. RadioMed sued ONC for misappropriation of RadioMed's trade secrets and use of them to develop a competing linear fiducial marker called the X-Mark(TM).
COMPASS Provides Needed Flexibility for Optimal QA Efficiency Enabling Measurement -- as Well as Full 3D Calculation-Based Independent Treatment Plan Verification
Marketwire - Thu Aug 01, 5:34AM CDT
IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the launch of a milestone: COMPASS 3.0 plan verification system. COMPASS, the first patient anatomy- centric and most sophisticated solution for advanced IMRT and rotational plan verification now provides a new two-in-one solution: calculation-based full 3D independent Treatment Plan System (TPS) verification and measurement-based Quality Assurance (QA) for the complete treatment chain, including linear accelerators. COMPASS offers superior full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need. This announcement will be made at the 55th American Association of Physicists in Medicine Annual Meeting and Exhibition, Booth 1035.
Zevacor Molecular Awards IBA Contract to Build Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
PR Newswire - Mon Nov 04, 4:09PM CST
Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A., (IBA).
IBA to Install the First Commercial 70 MeV Cyclotron Dedicated to the Production of Radiopharmaceuticals in the United States
GlobeNewswire - Mon Nov 04, 12:46AM CST
IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy and radiopharmacy solutions, today announces it has signed a formal contract with Zevacor Molecular for the installation of its Cyclone 70 in the United States. This will be the first commercial 70 MeV Cyclotron dedicated to radiopharmaceuticals production in the country. The installation of the system is worth between $16 and 20 million to IBA. The project financing is fully secured. The Cyclone 70 Cyclotron is expected to be operational in the second half of 2016.
IBA Successfully Concludes Litigation Over Competing Fiducial Marker
Marketwire - Tue Aug 06, 5:08AM CDT
IBA (Ion Beam Applications S.A.) (EURONEXT BRUSSELS: IBAB), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the execution of a Letter of Intent to resolve litigation and claims of IBA subsidiary RadioMed Corp. against ONC Solutions, Inc. RadioMed sued ONC for misappropriation of RadioMed's trade secrets and use of them to develop a competing linear fiducial marker called the X-Mark(TM).
COMPASS Provides Needed Flexibility for Optimal QA Efficiency Enabling Measurement -- as Well as Full 3D Calculation-Based Independent Treatment Plan Verification
Marketwire - Thu Aug 01, 5:34AM CDT
IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the launch of a milestone: COMPASS 3.0 plan verification system. COMPASS, the first patient anatomy- centric and most sophisticated solution for advanced IMRT and rotational plan verification now provides a new two-in-one solution: calculation-based full 3D independent Treatment Plan System (TPS) verification and measurement-based Quality Assurance (QA) for the complete treatment chain, including linear accelerators. COMPASS offers superior full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need. This announcement will be made at the 55th American Association of Physicists in Medicine Annual Meeting and Exhibition, Booth 1035.
(0)
(0)